Non-small Cell Lung Cancer
Conditions
Keywords
Non-small cell lung cancer,Endostar
Brief summary
Research purpose: Degree of continuous intravenous pumping Endostar (human recombinant endostatin) combination chemotherapy regimens including cisplatin two medicine first-line treatment of advanced non-small cell lung cancer (with the exception of EGFR/ALK mutations) efficacy and safety.
Detailed description
1.Research purpose: Degree of continuous intravenous pumping Endostar (human recombinant endostatin) combination chemotherapy regimens including cisplatin two medicine first-line treatment of advanced non-small cell lung cancer (with the exception of EGFR/ALK mutations) efficacy and safety. 2.1 main objectives: PFS 2.2 the secondary goal: 2.2. 1 ORR, DCR and OS 2.2. 2 the quality of life 3. The study design 3.1 research nature This is a single arm, multicenter clinical study, is expected to total 100 patients into the group. Hierarchical factors include: the tumor staging (Ⅲ B vs Ⅳ), ECOG score (0 v 1), gender (male vs female). 3.2 research center and research Proposed by taizhou people's hospital and medical association of jiangsu province tumor chemotherapy and biological branch of the lung cancer group led by several large and medium-sized hospitals in the province of the malignant tumor treatment related department to participate, in accordance with the unified test plan of this research.
Interventions
BIOLOGICALEndostar
Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles
DRUGChangchun marina
25mg/m2,d1 and d8,q21d×4
DRUGcisplatin
80mg/m2,d1, q21d×4
DRUGTaxol
135-175mg/m2,d1,q21d×4
DRUGparapl
AUC=5-6,d1,q21d×4
Sponsors
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Histologic confirmation cytology or not in patients undergoing single sputum cytology in the diagnosis of patients with non-small cell lung cancer; * according to a new IASLC2009 lung cancer TNM stages judged the preious untreated stage IIIB or IV non-small cell lung cancer (with the exception of EGFR/ALK mutations type); * must have at least one according to the RRECIST version 1.1 standard judgment to evaluate lesions (at least 10 mm, maximum diameter on spiral CT plain CT longest diameter at least 20 mm); * male or female, age 18 and 75 years old or less or more; * ECOG PS 0 \ 1 minute; * is expected to survive period for 3 months or more, * enough blood function: absolute neutrophil count (ANC) or 2 x 109 / L and the platelet count 100 x 109 / L or higher acuity 9 g/dL and hemoglobin; * Liver function enough: upper limit of total bilirubin acuities were normal (ULN); AST and ALT acuities were 2.5 times the upper limit of normal (ULN); Alkaline phosphatase 5 times the upper limit of normal or less (ULN); * enough renal function, serum creatinine or less normal limit (ULN) or calculated creatinine clearance or 60 mL/min. * basic normal ecg, had on the body to heal wounds; * always not received anti-tumor drug therapy, or always only for non metastatic tumor of adjuvant or neoadjuvant chemotherapy, but to study treatment has ended more than six months at the beginning; * ever had had surgery patients, request to study treatment began to have more than 4 weeks, and the patient has recovered; * a complete uterus of female in the group within 28 days before the study must have a negative pregnancy test results (except amenorrhea has 24 months). If the pregnancy test from the first time for more than 7 days, is the need for urine pregnancy test validation (within 7 days before the first delivery). * prior to biological agents, especially e. coli genetically engineered products without severe allergic reactions; * signed informed consent.
Exclusion criteria
* pregnancy, nursing mothers, or fertility but not women using contraception; * the existing serious acute infection, and not be controlled; Or fester sex and chronic infection, wound in delay no more; * the original serious heart disease, including: higher risk of congestive heart failure, unable to control arrhythmia, unstable angina, myocardial infarction, severe valvular heart disease, and resistant hypertension; * is not easy to control nerve, mental illness or mental disorders, compliance is poor, can't cooperate with accounts and response to treatment; Primary brain tumors or CNS metastases illness did not get a control, has obvious symptoms in cranial hypertension or nerve spirit; * with bleeding tendency; * other researchers believe that patients should not participate in this test.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS（progression-free survival） | Change from Baseline at the week 6,12, 18 of treatment phase and the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase | PFS is refers to the patients randomly into group to the date of any objective records of patients with tumor progression or death time. |
Secondary
| Measure | Time frame |
|---|---|
| ORR（Objective Response Rate） | 1 weeks before treatment, Change from Baseline at the week 6,12, 18 of treatment phase and the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase |
| DCR(disease control rate) | Change from Baseline at the week 6,12, 18 of treatment phase and the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase |
| OS（overall survival） | Change from Baseline at the week 6,12, 18 of treatment phase and the month 3, 6, 9 and 12, 15, 18, 21, 24, 27, 30 ,33,36 of the followup phase |
Countries
China
Contacts
Primary ContactYin Qingfeng, manager
Outcome results
None listed